Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niven Mehra

Showing results (111-120 of 161) with videos related to

Pageof 17
Sort By:
Prostate Cancer and Prostatic Diseases|October 12, 2022
Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registryGijs P A van den Bergh, Malou C P Kuppen, Hans M Westgeest, et al.
The Journal of Clinical Investigation|October 1, 2024
Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancerXiaolin Zhu, Tatyanah Farsh, Daniël Vis, et al.
Prostate Cancer and Prostatic Diseases|July 8, 2022
Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapyMaarten J van der Doelen, Irma M Oving, Dirk N J Wyndaele, et al.
Clinical Genitourinary Cancer|December 1, 2021
Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the NetherlandsMalou C P Kuppen, Hans M Westgeest, Alfons J M van den Eertwegh, et al.
European Urology|January 28, 2022
Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial CarcinomaJ Alberto Nakauma-González, Maud Rijnders, Job van Riet, et al.
JCI Insight|January 30, 2025
Multimodal integration of blood RNA and ctDNA reflects response to immunotherapy in metastatic urothelial cancerSandra van Wilpe, Davide Croci, Sara S Fonseca Costa, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 29, 2024
The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of <sup>223</sup>Ra Therapy in Metastatic Castration-Resistant Prostate Cancer PatientsDianne Bosch, Kim J M van der Velden, Irma M Oving, et al.
NEJM Evidence|February 6, 2024
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate CancerNoel W Clarke, Andrew J Armstrong, Antoine Thiery-Vuillemin, et al.
BJU International|September 2, 2025
Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancerMichiel Vlaming, Wouter Koole, R Jeroen A van Moorselaar, et al.
Prostate Cancer and Prostatic Diseases|July 13, 2021
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancerBastiaan M Privé, Peter H J Slootbeek, Babette I Laarhuis, et al.
Pageof 17

Showing results (111-120 of 161) with videos related to

Sort By:
Pageof 17
Prostate Cancer and Prostatic Diseases|October 12, 2022
Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registryGijs P A van den Bergh, Malou C P Kuppen, Hans M Westgeest, et al.
The Journal of Clinical Investigation|October 1, 2024
Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancerXiaolin Zhu, Tatyanah Farsh, Daniël Vis, et al.
Prostate Cancer and Prostatic Diseases|July 8, 2022
Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapyMaarten J van der Doelen, Irma M Oving, Dirk N J Wyndaele, et al.
Clinical Genitourinary Cancer|December 1, 2021
Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the NetherlandsMalou C P Kuppen, Hans M Westgeest, Alfons J M van den Eertwegh, et al.
European Urology|January 28, 2022
Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial CarcinomaJ Alberto Nakauma-González, Maud Rijnders, Job van Riet, et al.
JCI Insight|January 30, 2025
Multimodal integration of blood RNA and ctDNA reflects response to immunotherapy in metastatic urothelial cancerSandra van Wilpe, Davide Croci, Sara S Fonseca Costa, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 29, 2024
The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of <sup>223</sup>Ra Therapy in Metastatic Castration-Resistant Prostate Cancer PatientsDianne Bosch, Kim J M van der Velden, Irma M Oving, et al.
NEJM Evidence|February 6, 2024
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate CancerNoel W Clarke, Andrew J Armstrong, Antoine Thiery-Vuillemin, et al.
BJU International|September 2, 2025
Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancerMichiel Vlaming, Wouter Koole, R Jeroen A van Moorselaar, et al.
Prostate Cancer and Prostatic Diseases|July 13, 2021
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancerBastiaan M Privé, Peter H J Slootbeek, Babette I Laarhuis, et al.
Pageof 17